The mechanism of action of ICIs involves blocking immune checkpoints, such as programmed cell death protein 1 (PD-1)/PD-L1 and cytotoxic T-lymphocyte-associated antigen (CTLA)-4, thereby restoring the function of immune cells to attack cancer cells. Here, PDCD1 is linked to cancer.